Walgreens Boots Alliance Inc
WBA: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$36.00 | Vhgz | Bvwq |
Walgreens' Solid Q2 Results Driven by Strong Healthcare Business; Fair Value Estimate Remains $48
Walgreens Boots Alliance reported fiscal 2023 second-quarter results that were slightly better than we anticipated. Sales grew 3.3% year over year, driven by U.S. healthcare and international, with slight offsets from the core pharmacy business. We are maintaining our $48 fair value estimate.